J B Chemicals and Pharmaceuticals Ltd

J B Chemicals & Pharmaceuticals Ltd is down for a fifth straight session today. The stock is quoting at Rs 1731, down 1% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is down around 0.29% on the day, quoting at 26115.75. The Sensex is at 85365.62, down 0.31%.J B Chemicals & Pharmaceuticals Ltd has added around 1.3% in last one month.Meanwhile, Nifty Pharma index of which J B Chemicals & Pharmaceuticals Ltd is a constituent, has increased around 0.76% in last one month and is currently quoting at 22687.55, down 0.15% on the day. The volume in the stock stood at 1.69 lakh shares today, compared to the daily average of 2.14 lakh shares in last one month.The PE of the stock is 38.76 based on TTM earnings ending September 25.Powered by Capital Market - Live

Profit before tax (PBT) stood at Rs 279.15 crore in Q2 FY26, up 18% from Rs 236.53 crore reported in the corresponding quarter last year. In Q2 FY26, operating EBITDA stood at Rs 319 crore, up 12%, compared with Rs 285 crore posted in the same quarter last year. Operating EBITDA margin stood at 29.4% in Q2 FY26 as against 28.4% in Q2 FY25. Nikhil Chopra, CEO and whole-time director of JB Pharma, stated, 'The company's domestic business continued to outperform the market, with all major brands delivering robust growth. Our focus on driving steady volume growth across key brands'including recently acquired portfolios'continues to yield good results. On the international front, momentum in our CDMO business has returned, supported by a solid order book that positions us for further growth in the second half of the year. Over the years, JB has consistently delivered strong revenue and margin performance. We are confident in sustaining this positive momentum as we progress toward our operational and strategic goals for the current year and beyond. As we chart the path ahead, our focus remains on building a progressive, agile, and future-ready organization.' JB Chemicals & Pharmaceuticals manufactures a wide range of pharmaceutical formulation specialties, radiodiagnostics, APIs, and intermediates. Shares of JB Chemicals & Pharmaceuticals shed 0.41% to Rs 1,819.25 on the BSE.Powered by Capital Market - Live

Net profit of J B Chemicals & Pharmaceuticals rose 19.05% to Rs 207.82 crore in the quarter ended September 2025 as against Rs 174.57 crore during the previous quarter ended September 2024. Sales rose 8.42% to Rs 1084.90 crore in the quarter ended September 2025 as against Rs 1000.62 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales1084.901000.62 8 OPM %28.5427.04 - PBDT323.59278.41 16 PBT279.15236.53 18 NP207.82174.57 19 Powered by Capital Market - Live

J B Chemicals & Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 11 November 2025.Powered by Capital Market - Live

J B Chemicals & Pharmaceuticals Ltd rose for a third straight session today. The stock is quoting at Rs 1696.1, up 1.48% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.6% on the day, quoting at 25738.2. The Sensex is at 83911.27, up 0.53%. J B Chemicals & Pharmaceuticals Ltd has added around 0.31% in last one month. Meanwhile, Nifty Pharma index of which J B Chemicals & Pharmaceuticals Ltd is a constituent, has added around 1.46% in last one month and is currently quoting at 22103.2, up 0.64% on the day. The volume in the stock stood at 89803 shares today, compared to the daily average of 1.7 lakh shares in last one month.The PE of the stock is 38.64 based on TTM earnings ending June 25.Powered by Capital Market - Live

J B Chemicals & Pharmaceuticals has allotted 114,999 equity shares under ESOS on 14 August 2025. Consequently, the issued, subscribed and paid up capital has increased from 15,63,41,004 equity shares of Re. 1 each to 15,64,56,003 equity shares of Re. 1 each. Powered by Capital Market - Live

J B Chemicals & Pharmaceuticals has allotted 23,003 equity shares under ESOS on 09 August 2025. Consequently, the issued, subscribed and paid up capital has increased from 15,63,18,001 equity shares of Re. 1 each to 15,63,41,004 equity shares of Re. 1 each. Powered by Capital Market - Live

J B Chemicals & Pharmaceuticals Ltd dropped for a fifth straight session today. The stock is quoting at Rs 1693.4, down 1.11% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is down around 0.4% on the day, quoting at 24624.55. The Sensex is at 80672.42, down 0.43%.J B Chemicals & Pharmaceuticals Ltd has gained around 3.71% in last one month.Meanwhile, Nifty Pharma index of which J B Chemicals & Pharmaceuticals Ltd is a constituent, has eased around 2.06% in last one month and is currently quoting at 22153.8, down 1.12% on the day. The volume in the stock stood at 1.49 lakh shares today, compared to the daily average of 4.34 lakh shares in last one month.The PE of the stock is 39.54 based on TTM earnings ending June 25.Powered by Capital Market - Live

Profit before tax (PBT) stood at Rs 271.61 crore in Q1 FY26, rising 13.25% from the Rs 239.84 crore recorded in Q1 FY25. In Q1 FY26, operating EBITDA stood at Rs 330 crore, up 13%, compared with Rs 292 crore posted in the same quarter last year. Operating EBITDA margin stood at 30.2% in Q1 FY26 as against 29% in Q1 FY25. Nikhil Chopra, CEO and whole-time director of JB Pharma, stated, 'JB continues to be the fastest-growing domestic pharma company amongst the top 25 organizations as per IQVIA MAT Jun'25 data. The domestic business recorded approximately 14% value growth. This was driven by acute and chronic segments, including our ophthalmology portfolio. Our major brands & their franchises are also performing well. The CDMO business momentum is likely to be sustained in coming quarters. Our operating EBITDA margins crossed 30% for the first time, which highlights the results of our strategy of focusing on profitable growth. Going forward, we will maintain focus on driving topline growth, cost optimization, and organizational efficiencies. I am confident that the organization will continue to perform well, with our domestic and CDMO segments leading the way on growth and profitability. We have all the necessary building blocks in place for sustainable growth in the coming years.' JB Chemicals & Pharmaceuticals manufactures a wide range of pharmaceutical formulation specialties, radiodiagnostics, APIs, and intermediates.Powered by Capital Market - Live

Net profit of J B Chemicals & Pharmaceuticals rose 14.45% to Rs 202.38 crore in the quarter ended June 2025 as against Rs 176.83 crore during the previous quarter ended June 2024. Sales rose 8.91% to Rs 1093.94 crore in the quarter ended June 2025 as against Rs 1004.40 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales1093.941004.40 9 OPM %27.5027.91 - PBDT314.31280.62 12 PBT271.61239.84 13 NP202.38176.83 14 Powered by Capital Market - Live